)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
RedHill Biopharma
RedHill Biopharma (RDHL) investor relations material
RedHill Biopharma H1 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2026 earnings summary30 Sep, 2026
Executive summary
Strategic portfolio reset added exclusive commercialization rights to Rebyota and Clenpiq for $12M upfront, funded by the $18M upfront Talicia divestment proceeds.
Rebyota and Clenpiq generated a combined $37.5M in 2025 net sales under Ferring; the portfolio is supported by an established U.S. GI commercial infrastructure.
H1 2026 priorities included transitioning the two products and advancing oncology, Crohn’s disease, Ebola and other GI development programs.
Financial highlights
Continuing-operations revenue was $0 in H1 2026 vs. $0.3M in H1 2025, generated from the RHB-102 license agreement.
Operating loss was $4.1M vs. $3.4M; net loss was $6.1M vs. $4.1M in H1 2025.
Net financial expense was $1.6M vs. $0.5M net financial income in H1 2025, mainly reflecting warrant issuance costs and derivative fair-value adjustments.
Outlook and guidance
Priorities for H2 2026 and beyond include smooth product transitions, commercial growth, further complementary product additions and continued R&D progress.
Opaganib remains in a Bayer-supported Phase 2 prostate cancer study; recruitment continues, while the RHB-204 Crohn’s program is Phase 2-ready.
RHB-102 development includes GI intolerance associated with GLP-1/GIP therapies; a Phase 2-ready proof-of-concept study is planned.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from RedHill Biopharma
- Talicia® leads a late-stage pipeline with strong efficacy, broad coverage, and robust IP protection.RDHL
Corporate presentation - Biopharma firm registers 26.2M ADSs for resale, with proceeds from warrants for R&D and operations.RDHLRegistration filing
- Talicia dominates as a first-line H. pylori therapy, driving growth and pipeline advancement.RDHLCorporate presentation
- Talicia dominates H. pylori therapy as a robust pipeline targets GI, infectious, and cancer markets.RDHLCorporate presentation
- Strategic partnerships and licensing drove improved equity and R&D progress despite operating losses.RDHLH2 2025
- Talicia leads H. pylori therapy, supported by strong financials and a diversified late-stage pipeline.RDHLCorporate presentation
- Strong U.S. growth, leading H. pylori therapy, and robust late-stage pipeline drive momentum.RDHLCorporate presentation
- Up to 6.47M ADSs may be sold for $25M, with proceeds for general use amid operational risks.RDHLRegistration Filing
- Up to 6.47M ADSs may be sold for up to $25M, with major dilution and operational risks.RDHLRegistration Filing
Next RedHill Biopharma earnings date
H2 202626 Apr, 2027
RedHill Biopharma
Next RedHill Biopharma earnings date
H2 202626 Apr, 2027
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage